A Phase II Trial of BBR 3464 as First Line Treatment in Patients With Inoperable, Locally Advanced or Metastatic Adenocarcinoma of the Pancreas
OBJECTIVES: I. Determine the overall survival of patients with inoperable locally advanced
or metastatic adenocarcinoma of the pancreas treated with BBR 3464. II. Determine the
response rate, duration of response, time to disease progression, and duration of stable
disease in patients treated with this drug. III. Determine the incidence and severity of the
toxic effects of this drug in these patients. IV. Determine the disease-related symptoms in
patients treated with this drug.
OUTLINE: This is a multicenter study. Patients receive BBR 3464 IV over 1 hour on day 1.
Treatment repeats every 21 days for a minimum of 6 courses in the absence of disease
progression or unacceptable toxicity. Patients are followed every 9 weeks.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Primary Purpose: Treatment
George L. Miller, MD
Oklahoma Oncology, Incorporated at LaFortune Cancer Center
United States: Federal Government
|Albert B. Chandler Medical Center, University of Kentucky||Lexington, Kentucky 40536-0084|
|Robert H. Lurie Comprehensive Cancer Center, Northwestern University||Chicago, Illinois 60611|
|Beth Israel Deaconess Medical Center||Boston, Massachusetts 02215|
|Cancer Center at the University of Virginia||Charlottesville, Virginia 22908|
|Massey Cancer Center||Richmond, Virginia 23298-0037|
|Oklahoma Oncology Inc.||Tulsa, Oklahoma 74104|
|Alta Bates Comprehensive Cancer Center||Berkeley, California 94704|
|Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group||Memphis, Tennessee 38119|
|Arizona Oncology Associates||Tucson, Arizona 85712-2254|